IDEXX Laboratories (IDXX) 10-Q2023 Q1 Quarterly report

Filed: 2 May 23, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Brazil, challenging, Clarifying, constant, construction, create, deployment, Description, diversified, drawn, expenditure, food, industry, innovative, institution, magnitude, Maine, modification, North, participating, quantification, ruminant, satisfaction, Scarborough, scheduled, spread, uncertainty, understand, user, weaker

Removed: African, analyzer, Asia, back, bad, broader, building, Catalyst, clinical, closely, coli, coliform, Colilert, comparison, concentration, consist, continuing, cyberattack, cybersecurity, declined, delayed, disciplined, discontinuation, disruption, ease, elapsed, enable, enabled, enforcement, execute, export, factor, FASB, Fever, Finland, forecast, fourth, fully, government, half, heighten, high, implement, implemented, largely, LIBOR, live, managing, mitigating, mitigation, moderate, moderated, ninety, permitted, planning, political, pork, positioned, premium, presence, proactive, ProCyte, region, regulatory, reliably, relief, reputational, retaliatory, retention, Russia, Russian, sanctioned, scope, significantly, solid, strategy, suspending, sustained, swine, Switzerland, timeframe, transacted, transition, United, visit

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated IDXX transcripts

IDXX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the report on Form 10-Q of IDEXX Laboratories, Inc. (the “Company”) for the quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


			/s/ Brian P. McKeon
May 2, 2023			Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer

A signed original of this written statement required by Section 906, has been provided to IDEXX Laboratories, Inc. and will be retained by IDEXX Laboratories, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.